cytosine arabinoside


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to cytosine arabinoside: Daunorubicin

cytosine

 [si´to-sēn]
cytosine arabinoside cytarabine.

cy·to·sine ar·a·bi·no·side (CA, AraC),

1. a synthetic nucleoside used as an antimetabolite in the treatment of neoplasms;
2. incorrect term for arabinosylcytosine.

cytosine arabinoside

(ăr′ə-bĭn′ə-sīd′, ə-răb′ə-nō-sīd′)

cytosine arabinoside

cy·to·sine ar·a·bi·no·side

(CA) (sī'tō-sēn ar'ă-bin'ŏ-sīd)
1. A synthetic nucleoside used as an antimetabolite in the treatment of neoplasms.
2. Incorrect term for arabinosylcytosine.

cytosine

a pyrimidine base found in the nucleic acids, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

cytosine arabinoside
References in periodicals archive ?
Winter JN, Variakojis D, Gaynor ER, Larson RA, Miller KB (1985) Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
May 17 /PRNewswire/ -- Xanthus Life Sciences today announced the presentation of data from a Phase 1 study of Amonafide (now called Xanafide(TM)) in combination with cytosine arabinoside (ara-C) at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO).
announced today that initial clinical data from a Phase I trial of its anti-cancer agent CLORETAZINE(TM) (VNP40101M) in combination with cytosine arabinoside (Ara-C) in leukemia were presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in New Orleans, Louisiana.
Cytosine arabinoside (ARA-C) associated pulmonary toxicity is a well-described life-threatening complication of anti-leukemia therapy.
A preclinical study with Aplidin(R)* presented at this important oncology meeting has shown that sub-toxic concentrations of the agent act synergistically with the anti-cancer agents methotrexate, cytosine arabinoside and doxorubicin to make human leukaemia and lymphoma cell lines more sensitive to treatment.
azathioprine, cytosine arabinoside (Ara-C), hydroxyurea, and vincristine), or in all phases ('cell-cycle nonspecific").
A pre-clinical study with Aplidin(r) (1) presented at this important oncology meeting has shown that sub-toxic concentrations of the agent act synergistically with the anti-cancer agents methotrexate, cytosine arabinoside and doxorubicin to make human leukaemia and lymphoma cell lines more sensitive to treatment.